Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206986
Status:
COMPLETED
Last Update Posted:
2013-12-20
First Post:
2005-09-12
Brief Title:
Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia
Sponsor:
Birte Glenthoj
Organization:
University of Copenhagen
Study Overview
Official Title:
Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators want to try to improve information processing in schizophrenic patients via pharmacological intervention The hypothesis is that decreased noradrenergic activity will normalize information processing PPI P50 gating P300 and mismatch negativity in patients with schizophrenia
Detailed Description:
A number of reports in literature provide evidence for among others an increased central noradrenergic activity in schizophrenia In addition to this increased noradrenergic activity patients with schizophrenia often show reduced filtering of sensory information which is reflected in reduced P50 suppression and reduced prepulse inhibition of the startle reflex PPI In two separate initial studies in our laboratory we found reduced sensory gating following administration of imipramine a combined noradrenergic and serotonergic agonist and desipramine a highly specific noradrenergic agonist to healthy volunteers This provides evidence for a direct causal relation between the increased noradrenergic activity and the disturbed gating of sensory information as both commonly found in patients with schizophrenia Therefore in a follow-up study the effects of a noradrenergic antagonist will be investigated on the sensory gating of patients with schizophrenia To further extend the data of our initial studies the patients will additionally be tested for two psychophysiological parameters of attention that are usually found to be disturbed in patients with schizophrenia ie mismatch negativity and selective attention The design will conform to a double blind placebo controlled experiment in which either four doses 025 ug 50 ug 75 ug or 150 ugof clonidine or placebo will be added to the current medical treatment of 20 male patients with schizophrenia on five occasions separated by at least a week after which they are tested in the Copenhagen Psychophysiological Test Battery CPTBIn order to test the effects of clonidine in healthy volunteers 20 healthy males will receive a fixed dose of 015 mg clonidine or placebo on two separate occasions separated by at least a week after which they will be tested in the CPTB as well
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| KF 11-261729 | None | None | None |